2014
DOI: 10.1016/j.biomaterials.2014.01.035
|View full text |Cite
|
Sign up to set email alerts
|

Cisplatin–alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
46
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 109 publications
(50 citation statements)
references
References 24 publications
1
46
0
Order By: Relevance
“…It interacts with guanine and adenine N7 atoms located in the DNA major groove, leading to DNA bending and interfering with its replication, transcription as well as other nuclear functions, thus, arresting cancer cell proliferation and tumor growth (Cepeda et al, 2007). Despite its clinical success, intravenous Cis administration can lead to nephrotoxicity, bone marrow toxicity, intractable vomiting, peripheral neuropathy, deafness, seizures and blindness (Genc et al, 2014;Wang et al, 2014). Drug resistance during therapy is another important limitation to its use requiring the use of increasing doses (Dzamitika et al, 2006).…”
Section: Introductionmentioning
confidence: 99%
“…It interacts with guanine and adenine N7 atoms located in the DNA major groove, leading to DNA bending and interfering with its replication, transcription as well as other nuclear functions, thus, arresting cancer cell proliferation and tumor growth (Cepeda et al, 2007). Despite its clinical success, intravenous Cis administration can lead to nephrotoxicity, bone marrow toxicity, intractable vomiting, peripheral neuropathy, deafness, seizures and blindness (Genc et al, 2014;Wang et al, 2014). Drug resistance during therapy is another important limitation to its use requiring the use of increasing doses (Dzamitika et al, 2006).…”
Section: Introductionmentioning
confidence: 99%
“…Cisplatin (CDDP)-sodium alginate (SA)-liposome may be a promising formulation for delivery of CDDP in treatment of ovarian carcinoma with enhanced efficiency and fewer adverse effects. Since epidermal growth factor receptor (EGFR) is overexpressed in many ovarian cancers, EGF was used for active targeting [42]. Moreover, biomolecules such as DNA and proteins can be entrapped in alginate matrices by relatively mild gelation processes and free of organic solvents.…”
Section: Application Of Alginate In Drug Deliverymentioning
confidence: 99%
“…Lin et al also showed that cisplatin‐incorporated gelatin nanoparticles (GP) with biotinylated‐EGF (bEGF) modification (GP‐Pt‐bEGF) resulted in much higher Pt concentrations in A549 cells (high EGFR expression) than in HFL1 cells (low EGFR expression) . EGF modified liposomes carrying cisplatin (CS‐EGF‐Lip) showed enhanced drug delivery to EGFR‐positive ovarian tumor tissues and improved antitumor efficacy with much lower system toxicity in mice . Cetuximab (CTX), a monoclonal antibody (mAb), was used to treat certain (wild‐type KRAS) metastatic colorectal cancer (CRC) expressing EGFR.…”
Section: Targeted Deliverymentioning
confidence: 99%